Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Skin Neoplasms 1Melanoma 1

Interventions

Cyclophosphamide 548pembrolizumab 384Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × Toll-Like Receptor 1 × Clear all
NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
13 enrolled 10 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT04111510 2024-11-21

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Yale University

Phase 2 Completed
6 enrolled 13 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡